Ex-US FDA Director John Jenkins Sketches Regulatory Path For Esperion's Bempedoic Acid

Esperion Therapeutics Inc.' analyst day on July 10 featured two pharmaceutical luminaries speaking on behalf of its key developmental product bempedoic acid: Ex-US FDA official John Jenkins offered reassurances to investors about the regulatory path forward for the novel oral cholesterol drug and Steve Nissen, study chair of the CLEAR outcomes study, vouched for the product's safety.

Bempedoic acid is a first-in-class inhibitor of ATP citrate lyase (ACL) that upregulates the LDL-C receptor in order to reduce cholesterol synthesis